| miR-16 expression analysis | Description of tissue sample | ||||
| Human FFPE tissue from different organs (see fig 2) | Normal lymphoid tissue (n = 8) | Intestine (n = 11): tubular adenoma (3), tubulo-villous adenoma (1), tubular adenoma high-grade dysplasia (1), ulcerative colitis (3), Crohn disease (1), collagenous colitis (1) | Bone marrow (n = 9): chronic idiopathic myelofibrosis (3), polycythaemia vera (3), essential thrombocythaemia (3) | Liver (n = 15): normal transplant organ (2), breast carcinoma metastasis (1), colon carcinoma met (4), small cell lung carcinoma metastasis (1), HCV+cirrhosis (1), HCV+mild fibrosis (1), HBV+moderate fibrosis (2), steatohepatitis (3) | Breast (n = 15): fibroadenoma (4), fibrocystic tissue (5), normal with calcifications (1), invasive ductal carcinoma (4), DCIS (1) |
| FFPE versus snap-frozen tissues (see fig 1C) | FFPE human liver tissue (n = 4) | FFPE human colon tissue (n = 3) | Snap-frozen human liver tissue (n = 4) | Snap-frozen human colon tissue (n = 3) | |
| Length of archival tissue storage (see fig 4) | 7 years: human lymph nodes, FFPE (n = 7) | 17 years: human lymph nodes, FFPE (n = 7) | 27 years: human lymph nodes, FFPE (n = 7) | Present day: human lymph nodes, FFPE (n = 11) | |
DCIS, ductal carcinoma in-situ; FFPE, formalin-fixed paraffin-embedded; HBV, hepatitis B virus; HCV, hepatitis C virus; miR-16, miR-16 microRNA.